Andere talen Takeda Pharmaceutical Company Limited London S.E.

Aandelen

0A87

US8740602052

Vertraagde tijd London S.E. Andere beurzen 16:57:19 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
12,88 ^USD	+1,13%		+1,89%	-9,43%

25/06	Amerikaanse CDC waarschuwt zorgverleners voor toename van denguegevallen	RE
25/06	Takeda's geneesmiddel tegen kanker krijgt goedkeuring van Europese Commissie	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Takeda anuncia el nombramiento de nuevos cargos directivos	05:58
Takeda kündigt neue Besetzung der Direktorenposten an	01:44
Takeda annonce de nouvelles nominations de directeurs	01:26
TAKEDA PHARMACEUTICAL : Form 6 K	26/06
Takeda Pharmaceutical : Announces New Assignments of Directors Form 6 K	26/06
Takeda Announces New Assignments of Directors	26/06
US CDC alerts healthcare providers of increase in dengue cases	25/06
Takeda's Cancer Drug Gets European Commission Approval	25/06
Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24/06
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24/06
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	24/06
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24/06
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	24/06
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	24/06
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	24/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21/06
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	21/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Takeda Pharmaceutical Company Limited London S.E.

Aandelen

0A87

US8740602052

Andere talen

Filters